

## **Conclusions and Recommendations**

CRT is an effective procedure for treatment of moderate to severe heart failure with LVEF < 35%, sinus rhythm who remains symptomatic despite optimal medical treatment.

QRS duration $\geq$ 150msec, dilated cardiomyopathy, TAPSE $\geq$ 15 mm, sinus rhythm, absence of COPD , absence of history of renal disease and optimal LV lead position were the independent predictors of CRT response.

The newly generated CRTscore (in parallel to the current guidelines) may be used to improve patient selection for CRT implantation in order to increase the CRT response rate.

We highly recommend further studies to validated the newly generated CRTscore.

### **Limitations of the study**

1. Small number of patients in NYHA IV included.
2. Small number of patients in AF included, small number of them underwent AV nodal ablation.
3. Small number of patients with narrow QRSd included.
4. Small number of patients with RBBB included.
5. Small number of patients with LV lead position in the anterior, anterolateral, basal and apical regions included.
6. Small number of echocardiographic parameters of mechanical dyssynchrony was assessed and other parameters (especially in TVI, strain and strain rate) were not measured.
  7. Automated device based optimization was the only optimization technique used.

## Summary

Heart failure is one of the most important causes of morbidity and mortality in the industrialized world.<sup>(1)</sup> Left ventricular activation delay, as indicated by widening of the QRS complex on a twelve lead electrocardiogram, is present in approximately one-quarter to one-third of heart failure patients. Widening of the QRS complex is a significant predictor of worsened LV systolic dysfunction and poorer outcomes in patients with heart failure.<sup>(7)</sup> Cardiac resynchronization therapy has been used to improve both the electrical and mechanical dyssynchrony in heart failure patients to improve patient morbidity and mortality.<sup>(8)</sup> It is generally estimated that 30-40% of patients meeting implantation guidelines fail to respond.<sup>(11)</sup> Therefore, how to predict who will respond to CRT remains an important and largely unanswered question.<sup>(11)</sup> Prediction of response to CRT is an important goal in order to derive the desired benefit.<sup>(11)</sup>

**The aim** of the study is to assess and identify the best predictors of CRT response.

**PATIENTS AND METHODS:** Patients with moderate to severe heart failure and LVEF $\leq$ 35% scheduled for CRT device implantation were subjected to history taking, clinical examination, ECG, echocardiography and coronary angiography in selected patients. CRT was implanted in all patients. CRT response was assessed 6-12 months after implantation. Data were analyzed using SPSS for Windows, version 20.

**Results:** One hundred and seventy patients were included (mean age  $68.8 \pm 9.7$  years, 38 females and 132 males). Ninety-one patients had dilated cardiomyopathy (DCM) and 79 patients had ischemic cardiomyopathy (ICM). Twenty-three patients presented in NYHA class II dyspnea, 136 NYHY class III and 11 ambulatory NYHA class IV at time of CRT implantation. The mean baseline QRS duration was  $145 \pm 25$  msec, 55.3% of patients had LBBB. During CRT implantation, 147 (86.5%) patients were in sinus rhythm, whereas 23 (13.5%) were in AF. The mean left ventricular internal dimension at end diastole (LVIDd) was  $67.6 \pm 9$  mm, the mean left

ventricular internal dimension at end systole (LVIDs) was  $55.7 \pm 10$  mm, the mean left ventricular end diastolic volume (LVEDV) was  $205.7 \pm 66$  ml and the mean left ventricular end systolic volume (LVESV) was  $148.3 \pm 56$  ml. The mean left ventricular ejection fraction was  $28.3 \pm 7$  %. The mean RV dimension at end diastole (RVd) was  $34.15 \pm 5.9$  mm and the mean tricuspid annular peak systolic excursion (TAPSE) was  $18.16 \pm 3.8$  mm. CRT-P was implanted in 65 patients and CRT-D was implanted in 105 patients. CRT response was achieved in 114 patients (67.1%). CRT implantation was associated with significant improvement in LV dimensions, functions and markers of LV dys-synchrony. CRT implantation was associated with improvement in NYHA class and 6 min walk distance. CRT was also associated with significant improvement in LV diastolic dysfunction and the grade of mitral regurgitation. Compared to non-responders, responders had significantly wider baseline QRS duration, lower BMI, lower baseline serum creatinine level, smaller baseline RV diastolic dimension and significantly greater tricuspid annular peak systolic excursion (TAPSE) value. In univariate analysis, female gender, absence of COPD, absence of history of renal disease, QRS duration  $\geq 150$  msec, LBBB, sinus rhythm, TAPSE  $\geq 15$  mm, RVd  $< 35$  mm, PAP  $< 50$  mmHg, absence of grade III LV diastolic dysfunction, SPWMD  $\geq 130$  msec, IVD  $\geq 40$  msec, Ts-septal-lateral  $\geq 60$  msec, dilated cardiomyopathy and optimal LV position were significant predictors of CRT response. In multinomial regression analysis to identify the preimplantation predictors of response; QRS duration  $\geq 150$  msec, dilated cardiomyopathy, TAPSE  $\geq 15$  mm, sinus rhythm, absence of COPD and absence of history of renal disease were the independent predictors of CRT response. We generated a new CRTscore to predict responders to CRT. The score consists of maximum 9 point. The CRT response rate has been markedly different according to the CRTscore. Patients with CRTscore  $\geq 6$  had CRT response rate of 97.5% vs only 40.7% if CRTscore  $< 6$ ,  $P < 0.001$ . The CRTscore also did well for predicting CRT response in all classes of recommendations for CRT implantation according to the European guidelines.

**Conclusion:** CRT is an effective procedure for treatment of moderate to severe heart failure. QRS duration  $\geq 150$  msec, dilated cardiomyopathy,

TAPSE $\geq$ 15 mm, sinus rhythm, absence of COPD and absence of history of renal disease were the independent preimplantation predictors of CRT response. A new CRTscore may be of benefit to improve the CRT response.

## References

1. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. *Eur Heart J* 2005;26:1115–40.
2. Cowie MR, Mosterd A, Wood DA, Poole-Wilson PA, Sutton GC, Grobbee DE. The epidemiology of heart failure. *Eur Heart J* 1997;18:208–25.
3. Murdoch DR, Love MP, Robb SD, et al. Importance of heart failure as a cause of death: changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979–1992. *Eur Heart J* 1998;19:1829–35.
4. Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? *Eur J Heart Fail* 1999;1:229–41.
5. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men—morbidity, risk factors and prognosis. *J Intern Med* 2001;249:253–61.
6. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. *Eur Heart J* 1999;20:421–8.
7. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. *J Am Coll Cardiol*. 2005;46:2183–92.
8. Singh JP, Gras D. Biventricular pacing: Current trends and future strategies. *Eur Heart J* 2012;33:305-13.
9. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. *N Engl J Med*. 2009;361:1329-38.
10. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. *N Engl J Med* 2010;363:2385-95.
11. Birnie DH, Tang AS. The problem of non-response to cardiac resynchronization therapy. *Curr Opin Cardiol* 2006;21:20-6.
12. Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). *Circulation* 2011;123:1061-72.
13. Cazeau S, Leclercq C, Lavergne T, et al. Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. *N Engl J Med*. 2001;344:873–80.
14. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. *N Engl J Med*. 2002;346:1845–53.

15. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med.* 2004;350:2140–50.
16. Cleland JGF, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med.* 2005;352:1539–49.
17. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. *J Am Coll Cardiol.* 2009;54:1837-46.
18. Adelstein EC, Saba S. Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization. *The American journal of cardiology.* 2009;103:238-42.
19. Rickard J, Kumbhani DJ, Gorodeski EZ, et al. Cardiac resynchronization therapy in non-left bundle branch block morphologies. *Pacing and clinical electrophysiology : PACE.* 2010;33:590-5.
20. Peterson PN, Greiner MA, Qualls LG, et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. *JAMA : the journal of the American Medical Association.* 2013;310:617-26.
21. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the heart rhythm society. *Journal of the American College of Cardiology.* 2013;61:e6-75.
22. Linde C, Ellenbogen K, McAlister FA. Cardiac resynchronization therapy (CRT): Clinical trials, guidelines, and target populations. *Heart rhythm* 2012;9:S3-13.
23. John J.V. McMurray, Stamatis Adamopoulos, Stefan D. Anker, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. *Eur Heart J.* 2012; 33:1787–847.

24. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *Circulation* 2005;112:1825–52.
25. Arnold JMO, Baker DW, Barnard DH, et al. HFSA 2006 comprehensive heart failure practice guideline. *J Card Fail*. 2006;1:E1–122.
26. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2008;117:E25–146.
27. McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. *J Am Coll Cardiol*. 2002;23:60–9.
28. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. *JAMA*. 2004;292:344–50.
29. Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and the aging population: an increasing burden in the 21<sup>st</sup> century? *Heart*. 2003;89:49–53.
30. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. *Eur Heart J*. 2005;26:384–416.
31. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. *Eur Heart J*. 2006;27:2725–36.
32. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in index admissions in Leicestershire 1993–2001. *Heart*. 2003;89:615–20.
33. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986 and 1995. *Circulation*. 2000;102:1126–31.
34. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. *N Engl J Med*. 2002;347:1397–402.
35. Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A. Decreasing oneyear mortality and hospitalization rates for heart failure in

- Sweden; data from the Swedish Hospital discharge registry 1988 to 2000. *Eur Heart J*. 2004;25:300–7.
36. McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ. Which inhibitor of the reninangiotensin system should be used in chronic heart failure and acute myocardial infarction? *Circulation*. 2004;110:3281–8.
37. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CARDiac RESynchronization-Heart Failure (CARE-HF) trial extension phase]. *Eur Heart J*. 2006;27:1928–32.
38. Mehra MR, Uber PA, Francis GS. Heart failure therapy at a crossroad: are there limits to the neurohormonal model? *J Am Coll Cardiol*. 2003;41:1606–10.
39. Kass DA. An epidemic of dissynchrony: but what does it mean? *J Am Coll Cardiol*. 2008;51:12–7.
40. Bleeker GB, Schalij MJ, Molhoek SG, et al. Relationship between QRS duration and left ventricular dyssynchrony in patients with end-stage heart failure. *J Cardiovasc Electrophysiol*. 2004;15:544–9.
41. Leclercq C, Cazeau S, Le Breton H, et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. *J Am Coll Cardiol*. 1998;32:1825–31.
42. Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy. *Pacing Clin Electrophysiol*. 1994;17:1974–9.
43. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular dysfunction: a systematic review. *JAMA*. 2007;297:2502–14.
44. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. *Nature*. 2008;451:919–28.
45. Hill JA, Olson EN. Cardiac plasticity. *N Engl J Med*. 2008;358:1370–80.
46. Michele Brignole, Angelo Auricchio, Gonzalo Baron-Esquivias, et al. ESC Guidelines on cardiac pacing and cardiac resynchronization therapy (2013). The task force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. *Eur Heart J* 2013;34:2281–329.
47. Iuliano S, Fish SG, Karasik PE, et al. QRS duration and mortality in patients with congestive heart failure. *Am Heart J*. 2002;143:1085–91.
48. Shamin W, Francis DP, Yousufuddin M, et al. Intraventricular conduction delay : a prognostic marker in chronic heart failure. *Int J Cardiol*. 1999;70:171–8.

49. Baldasseroni S, Gentile A, Gorini M, et al. Intraventricular conduction defects in patients with congestive heart failure: left but not right bundle branch block is an independent predictor of prognosis. A report from the Italian Network on Congestive Heart Failure (IN-CHF database). *Ital Heart J.* 2003;4:607–13.
50. De Winter O, Van de Veire N, Van Heuverswijn F, et al. Relationship between QRS duration, left ventricular volumes and prevalence of nonviability in patients with coronary artery disease and severe left ventricular dysfunction. *Eur J Heart Fail.* 2005;8:275–7.
51. Kearney MT, Zaman A, Eckberg DL, et al. Cardiac size and autonomic function, 5-year follow-up of chronic heart failure patients with severe prolongation of ventricular activation. *J Card Fail.* 2003;9:93–9.
52. Sandhu R, Bahler RC. Prevalence of QRS prolongation in a community hospital cohort of patients with heart failure and its relation to left ventricular systolic dysfunction. *Am J Cardiol.* 2004;93:244–6.
53. Murkofsky RL, Dangas G, Diamond JA, et al. A prolonged QR duration on surface electrocardiogram in a specific indicator of left ventricular dysfunction. *J Am Coll Cardiol.* 1998;32:476–82.
54. Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5,517 patients with congestive heart failure: a report from the Italian network on congestive heart failure. *Am Heart J.* 2002;143:398–405.
55. Stellbrink C, Auricchio A, Diem B, et al. Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. *Am J Cardiol.* 1999;83: D143–50.
56. Xiao HB, Roy C, Fujimoto S, Gibson DG. Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. *Int J Cardiol.* 1996;53:163–70.
57. Dye CL, Rosenbaum D, Lowe JC, et al. Primary myocardial disease part I: clinical features. *Ann Intern Med.* 1963;58:426–41.
58. Hofmann M, Bauer R, Handrock R, Weidinger G, Goedel-Meinen L. Prognostic value of the QRS duration in patients with heart failure: a subgroup analysis from 24 centers of Val-HeFT. *J Card Fail.* 2005;11:523–8.
59. Breidthardt T, Christ M, Matti M, et al. QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure. *Heart.* 2007;93:1093–7.
60. Prinzen FW, Spinelli JC, Auricchio A. Basic physiology and hemodynamics of cardiac pacing. In: Ellenbogen KA, Kay GN, Lau CP, Wilkoff BL, eds. *Clinical cardiac pacing, defibrillation, and resynchronization therapy.* Saunders, 2007:291–335.

61. Reckova M, Rosengarten C, deAlmeida A, et al. Hemodynamics is a key epigenetic factor in development of the cardiac conduction system. *Circ Res.* 2003;93:77–85.
62. Durrer D, van Dam RT, Freud GE, Janse MJ, Meijler FL, Arzbaecher RC. Total excitation of the isolated human heart. *Circulation.* 1970;41:899–912.
63. Scher AM. Studies of the electrical activity of the ventricles and the origin of the QRS complex. *Acta Cardiol.* 1995;50:429–65.
64. Fabiato A. Simulated calcium current can both cause calcium loading in and trigger calcium release from the sarcoplasmic reticulum of a skinned canine cardiac Purkinje cell. *J Gen Physiol.* 1985;85:291–320.
65. Cheng H, Lederer MR, Xiao RP, et al. Excitation-contraction coupling in heart: new insights from Ca<sup>2+</sup> sparks. *Cell Calcium.* 1996;20:129–40.
66. Prinzen FW, Augustijn CH, Allessie MA, Arts T, Delhaas T, Reneman RS. The time sequence of electrical and mechanical activation during spontaneous beating and ectopic stimulation. *Eur Heart J.* 1992;13:535–43.
67. Kuo LC, Quinones MA, Rokey R, Sartori M, Abinader EG, Zoghbi WA. Quantification of atrial contribution to left ventricular filling by pulsed Doppler echocardiography and the effect of age in normal and diseased hearts. *Am J Cardiol.* 1987;59:1174–8.
68. Karpawich PP, Mital S. Comparative left ventricular function following atrial, septal, and apical single chamber heart pacing in the young. *Pacing Clin Electrophysiol.* 1997;20:1983–8.
69. Vassallo JA, Cassidy DM, Miller JM, Buxton AE, Marchlinski FE, Josephson ME. Left ventricular endocardial activation during right ventricular pacing: effect of underlying heart disease. *J Am Coll Cardiol.* 1986;7:1228–33.
70. Auricchio A, Fantoni C, Regoli F, et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. *Circulation.* 2004;109:1133–9.
71. Zou Y, Akazawa H, Qin Y, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. *Nat Cell Biol.* 2004;6:499–506.
72. Zheng M, Han QD, Xiao RP. Distinct beta-adrenergic receptor subtype signaling in the heart and their pathophysiological relevance. *Sheng Li Xue Bao.* 2004;56:1–15.
73. Bers DM. Altered cardiac myocyte Ca regulation in heart failure. *Physiology Bethesda.* 2006;21:380–7.
74. Bers DM. Calcium cycling and signaling in cardiac myocytes. *Annu Rev Physiol.* 2008;70:23–49.

75. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. *Nature Reviews Drug Discovery*. 2007;6:1–18.
76. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signaling pathways. *Nat Rev Mol Cell Biol*. 2006;7:589–600.
77. Neubauer S. The failing heart—an engine out of fuel. *N Engl J Med*. 2007;356:1140–51.
78. Linke WA. Sense and stretchability: The role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. *Cardiovasc Res*. 2008;77:637–48.
79. Bleeker GB, Bax JJ, Steendijk P, Schalij MJ, van der Wall EE. Left ventricular dyssynchrony in patients with heart failure: pathophysiology, diagnosis and treatment. *Nat Clin Pract Cardiovasc Med*. 2006;3:213–9.
80. Li D, Farih S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. *Circulation*. 1999;100:87–95.
81. Han W, Chartier D, Li D, Nattel S. Ionic remodeling of cardiac Purkinje cells by congestive heart failure. *Circulation*. 2001;104:2095–100.
82. Severs NJ, Coppin SR, Dupont E, Yeh HI, Ko YS, Matsushita T. Gap junction alterations in human cardiac disease. *Cardiovasc Res*. 2004;62:368–77.
83. Poelzing S, Rosenbaum DS. Altered connexin-43 expression produces arrhythmia substrate in heart failure. *Am J Physiol Heart Circ Physiol*. 2004;287:H1762–70.
84. Verbeek XA, Vernooij K, Peschar M, Van Der Nagel T, Van Hunnik A, Prinzen FW. Quantification of interventricular asynchrony during LBBB and ventricular pacing. *Am J Physiol Heart Circ Physiol*. 2002;283:H1370–8.
85. Hawkins NM, Wang D, McMurray JJ, et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. *Eur J Heart Fail*. 2007;9:510–17.
86. Rodriguez MI, Sodi-Pallares D. The mechanism of complete and incomplete bundle branch block. *Am Heart J*. 1952;44:715–46.
87. Liu L, Tockman B, Girouard S, et al. Left ventricular resynchronization therapy in a canine model of left bundle branch block. *Am J Physiol Heart Circ Physiol*. 2002;282:H2238–44.
88. Varma N, Jia P, Rudy Y. Electrocardiographic imaging of patients with heart failure with left bundle branch block and response to cardiac resynchronization therapy. *J Electrocardiol*. 2007;40 Suppl:174–8.

89. Wyndham CR, Smith T, Meeran MK, Mammana R, Levitsky S, Rosen KM. Epicardial activation in patients with left bundle branch block. *Circulation*. 1980;61:696–703.
90. Cannom DS, Wyman MG, Goldreyer BN. Initial ventricular activation in left-sided intraventricular conduction defects. *Circulation*. 1980;62:621–31.
91. Vassallo JA, Cassidy DM, Marchlinski FE, et al. Endocardial activation of left bundle branch block. *Circulation*. 1984;69:914–23.
92. Rodriguez LM, Timmermans C, Nabar A, Beatty G, Wellens HJ. Variable patterns of septal activation in patients with left bundle branch block and heart failure. *J Cardiovasc Electrophysiol*. 2003;14:135–41.
93. Fung JW, Yu CM, Yip G, et al. Variable left ventricular activation pattern in patients with heart failure and left bundle branch block. *Heart*. 2004;90:17–19.
94. Xiao HB, Brecker SJ, Gibson DG. Effects of abnormal activation on the time course of the left ventricular pressure pulse in dilated cardiomyopathy. *Br Heart J*. 1992; 68:403–7.
95. Fantoni C, Kawabata M, Massaro R, et al. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using threedimensional non-fluoroscopic electroanatomic mapping system. *J Cardiovasc Electrophysiol*. 2005;16:112–21.
96. Peichl P, Kautzner J, Cihak R, Bytesnik J. The spectrum of inter- and intraventricular conduction abnormalities in patients eligible for cardiac resynchronization therapy. *Pacing Clin Electrophysiol*. 2004;27:1105–12.
97. Lambiase PD, Rinaldi A, Hauck J, et al. Non-contact left ventricular endocardial mapping in cardiac resynchronization therapy. *Heart*. 2004;90:44–51.
98. Hesse B, Diaz LA, Snader CE, Blackstone EH, Lauer MS. Complete bundle branch block as an independent predictor of all-cause mortality: report of 7,073 patients referred for nuclear exercise testing. *Am J Med*. 2001;110:253–9.
99. Fleg JL, Das DN, Lakatta EG. Right bundle branch block: long-term prognosis in apparently healthy men. *J Am Coll Cardiol*. 1983;1:887–92.
100. Eriksson P, Wilhelmsen L, Rosengren A. Bundle-branch block in middle-aged men: risk of complications and death over 28 years. The Primary Prevention Study in Goteborg, Sweden. *Eur Heart J*. 2005;26:2300–6.
101. Wong CK, Gao W, Stewart RA, et al. Risk stratification of patients with acute anterior myocardial infarction and right bundle branch block:

importance of QRS duration and early ST-segment resolution after fibrinolytic therapy. *Circulation*. 2006;114:783–9.

102. Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. *Circulation*. 1999;99:2993–3001.

103. Riedlbauchova L, Fridl P, Kautzner J, Peichl P. Performance of left ventricular versus biventricular pacing in chronic heart failure assessed by stress echocardiography. *Pacing Clin Electrophysiol*. 2004;27:626–31.

104. Touiza A, Etienne Y, Gilard M, Fatemi M, Mansourati J, Blanc JJ. Long-term left ventricular pacing: assessment and comparison with biventricular pacing in patients with severe congestive heart failure. *J Am Coll Cardiol*. 2001;38:1966–70.

105. Blanc JJ, Bertault-Valls V, Fatemi M, Gilard M, Pennec PY, Etienne Y. Midterm benefits of left univentricular pacing in patients with congestive heart failure. *Circulation*. 2004;109:1741–4.

106. Singh JP, Fan D, Heist EK, et al. Left ventricular lead electrical delay predicts response to cardiac resynchronization therapy. *Heart Rhythm*. 2006;3:1285–92.

107. Murphy RT, Sigurdsson G, Mulamalla S, et al. Tissue synchronization imaging and optimal left ventricular pacing site in cardiac resynchronization therapy. *Am J Cardiol*. 2006;97:1615–21.

108. Auricchio A, Ding J, Spinelli JC, et al. Cardiac resynchronization therapy restores optimal atrioventricular mechanical timing in heart failure patients with ventricular conduction delay. *J Am Coll Cardiol*. 2002;39:1163–9.

109. Verbeek XA, Auricchio A, Yu Y, et al. Tailoring cardiac resynchronization therapy using interventricular asynchrony. Validation of a simple model. *Am J Physiol Heart Circ Physiol*. 2006;290:H968–77.

110. Zuber M, Toggweiler S, Roos M, Kobza R, Jamshidi P, Erne P. Comparison of different approaches for optimization of atrioventricular and interventricular delay in biventricular pacing. *Europace*. 2008;10:367–73.

111. Toggweiler S, Zuber M, Kobza R, et al. Improved response to cardiac resynchronization therapy through optimization of atrioventricular and interventricular delays using acoustic cardiography: a pilot study. *J Card Fail*. 2007;13:637–42.

112. Vernooij K, Verbeek XA, Cornelussen RN, et al. Calculation of effective VV interval facilitates optimization of AV delay and VV interval in cardiac resynchronization therapy. *Heart Rhythm*. 2007;4:75–82.

113. Perego GB, Chianca R, Facchini M, et al. Simultaneous vs. sequential biventricular pacing in dilated cardiomyopathy: an acute hemodynamic study. *Eur J Heart Fail.* 2003;5:305–13.
114. Blendea D, Shah RV, Auricchio A, et al. Variability of coronary venous anatomy in patients undergoing cardiac resynchronization therapy: a high-speed rotational venography study. *Heart Rhythm.* 2007;4:1155–62.
115. Fung JW, Chan JY, Yip GW, et al. Effect of ventricular endocardial activation pattern on echocardiographic and clinical response to cardiac resynchronization therapy. *Heart.* 2007;93:432–7.
116. Akar FG, Spragg DD, Tunin RS, Kass DA, Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. *Circ Res.* 2004;95:717–25.
117. Byrne MJ, Helm RH, Daya S, et al. Diminished left ventricular dyssynchrony and impact of resynchronization in failing hearts with right versus left bundle branch block. *J Am Coll Cardiol.* 2007;50:1484–90.
118. Nelson GS, Curry CW, Wyman BT, et al. Predictors of systolic augmentation from left ventricular preexcitation in patients with dilated cardiomyopathy and intraventricular conduction delay. *Circulation.* 2000;101:2703–9.
119. Helm RH, Leclercq C, Faris OP, et al. Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: implications for assessing cardiac resynchronization. *Circulation.* 2005;111:2760–7.
120. Kawaguchi M, Murabayashi T, Fetters BJ, et al. Quantitation of basal dyssynchrony and acute resynchronization from left or biventricular pacing by novel echo-contrast variability imaging. *J Am Coll Cardiol.* 2002;39:2052–8.
121. Yu CM, Zhang Q, Fung JW, et al. A novel tool to assess systolic asynchrony and identify responders of cardiac resynchronization therapy by tissue synchronization imaging. *J Am Coll Cardiol.* 2005;45:677–84.
122. Bleeker GB, Mollema SA, Olman ER, et al. Left ventricular resynchronization is mandatory for response to cardiac resynchronization therapy. *Circulation.* 2007; 25;116:1440-8.
123. Henneman MM, Chen J, Ypenburg C, et al. Phase analysis of gated myocardial perfusion single-photon emission computed tomography compared with tissue Doppler imaging for the assessment of left ventricular dyssynchrony. *J Am Coll Cardiol.* 2007;49:1708–14.
124. Park RC, Little WC, O'Rourke RA. Effect of alteration of left ventricular activation sequence on the left ventricular end-systolic pressure–volume relation in closed-chest dogs. *Circ Res.* 1985;57:706–17.

125. Grover M, Glantz SA. Endocardial pacing site affects left ventricular end-diastolic volume and performance in the intact anesthetized dog. *Circ Res.* 1983;53:72–85.
126. Owen CH, Esposito DJ, Davis JW, Glower DD. The effects of ventricular pacing on left ventricular geometry, function, myocardial oxygen consumption, and efficiency of contraction in conscious dogs. *Pacing Clin Electrophysiol.* 1998;21:1417–29.
127. Helm RH, Byrne M, Helm PA, et al. Three-dimensional mapping of optimal left ventricular pacing site for cardiac resynchronization. *Circulation.* 2007;115:953–61.
128. Suga H, Goto Y, Yaku H, Futaki S, Ohgoshi Y, Kawaguchi O. Simulation of mechanoenergetics of asynchronously contracting ventricle. *Am J Physiol.* 1990;259:R1075–82.
129. Prinzen FW, Hunter WC, Wyman BT, McVeigh ER. Mapping of regional myocardial strain and work during ventricular pacing: experimental study using magnetic resonance imaging tagging. *J Am Coll Cardiol.* 1999;33:1735–42.
130. van Oosterhout MF, Arts T, Bassingthwaite JB, Reneman RS, Prinzen FW. Relation between local myocardial growth and blood flow during chronic ventricular pacing. *Cardiovasc Res.* 2002;53:831–40.
131. Vernooy K, Verbeek XA, Peschar M, et al. Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. *Eur Heart J.* 2005;26:91–8.
132. Nowak B, Sinha AM, Schaefer WM, et al. Cardiac resynchronization therapy homogenizes myocardial glucose metabolism and perfusion in dilated cardiomyopathy and left bundle branch block. *J Am Coll Cardiol.* 2003;41:1523–8.
133. Baller D, Wolpers HG, Zipfel J, Hoeft A, Hellige G. Unfavorable effects of ventricular pacing on myocardial energetics. *Basic Res Cardiol.* 1981;76:115–23.
134. Baller D, Wolpers HG, Zipfel J, Bretschneider HJ, Hellige G. Comparison of the effects of right atrial, right ventricular apex and atrioventricular sequential pacing on myocardial oxygen consumption and cardiac efficiency: a laboratory investigation. *Pacing Clin Electrophysiol.* 1988;11:394–403.
135. Spragg DD, Leclercq C, Loghmani M, et al. Regional alterations in protein expression in the dyssynchronous failing heart. *Circulation.* 2003;108:929–32.

136. Chakir K, Daya SK, Tunin RS, et al. Reversal of Global Apoptosis and Regional Stress Kinase Activation by Cardiac Resynchronization. *Circulation*. 2008;117:1369–77.
137. Spragg DD, Akar FG, Helm RH, Tunin RS, Tomaselli GF, Kass DA. Abnormal conduction and repolarization in late-activated myocardium of dyssynchronously contracting hearts. *Cardiovasc Res*. 2005;67:77–86.
138. Kies P, Bax JJ, Molhoek SG, et al. Effect of cardiac resynchronization therapy on inducibility of ventricular tachyarrhythmias in cardiac arrest survivors with either ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol*. 2005;95:1111–4.
139. Verbeek XA, Vernoooy K, Peschar M, Cornelussen RN, Prinzen FW. Intra-ventricular resynchronization for optimal left ventricular function during pacing in experimental left bundle branch block. *J Am Coll Cardiol*. 2003;42:558-67.
140. Prinzen FW, Cheriex EC, Delhaas T, et al. Asymmetric thickness of the left ventricular wall resulting from asynchronous electric activation: a study in dogs with ventricular pacing and in patients with left bundle branch block. *Am Heart J* 1995;130:1045-53.
141. Grines CL, Bashore TM, Boudoulas H, Olson S, Shafer P, Wooley CF. Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony. *Circulation* 1989;79:845-53.
142. Alonso C, Leclercq C, Victor F, et al. Electrocardiographic predictive factors of long-term clinical improvement with multisite biventricular pacing in advanced heart failure. *Am J Cardiol* 1999;84:1417-21.
143. Lambiase PD, Rinaldi A, Hauck J, et al. Non-contact left ventricular endocardial mapping in cardiac resynchronisation therapy. *HEART* 2004;90:44-51.
144. Curry CW, Nelson GS, Wyman BT, et al. Mechanical dyssynchrony in dilated cardiomyopathy with intraventricular conduction delay as depicted by 3D tagged magnetic resonance imaging. *Circulation* 2000;101:E2-8.
145. Fauchier L, Marie O, Casset-Senon D, Babuty D, Cosnay P, Fauchier JP. Reliability of QRS duration and morphology on surface electrocardiogram to identify ventricular dyssynchrony in patients with idiopathic dilated cardiomyopathy. *Am J Cardiol* 2003;92:341-4.
146. Toussaint JF, Lavergne T, Ollitraut J, et al. Biventricular pacing in severe heart failure patients reverses electromechanical dyssynchronization from apex to base. *PACE* 2000; 23:1731-4.
147. Toussaint JF, Lavergne T, Kerrou K, et al. Basal asynchrony and resynchronization with biventricular pacing predict long-term improvement of LV function in heart failure patients. *PACE*. 2003;26:1815-23.

148. Kerwin WF, Botvinick EH, O'Connell JW, et al. Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. *J Am Coll Cardiol* 2000;35:1221-7.
149. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. *J Am Soc Echocardiogr.* 1989;2:358-67.
150. Gorcsan J, Strum DP, Mandarino WA, Gulati VK, Pinsky MR. Quantitative assessment of alterations in regional left ventricular contractility with color-coded tissue Doppler echocardiography - Comparison with sonomicrometry and pressure-volume relations. *Circulation* 1997;95:2423-33.
151. Zamorano J, Wallbridge DR, Ge J, Drozd J, Nesser J, Erbel R. Non-invasive assessment of cardiac physiology by tissue Doppler echocardiography - A comparison with invasive haemodynamics. *Eur Heart J* 1997;18:330-9.
152. Heimdal A, Stoylen A, Torp H, Skjaerpe T. Real-time strain rate imaging of the left ventricle by ultrasound. *J.Am.Soc.Echocardiogr.* 1998;11:1013-9.
153. Urheim S, Edvardsen T, Torp H, Angelsen B, Smiseth OA. Myocardial strain by Doppler echocardiography. Validation of a new method to quantify regional myocardial function *Circulation* 2000;102:1158-64.
154. Edvardsen T, Gerber BL, Garot J, Bluemke DA, Lima JA, Smiseth OA. Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against three-dimensional tagged magnetic resonance imaging. *Circulation* 2002;106:50-6.
155. Pitzalis MV, Iacoviello M, Romito R, et al. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. *J Am Coll Cardiol* 2002;40:1615-22.
156. Pitzalis MV, Iacoviello M, Romito R, Guida P, De Tommasi E, Luzzi G et al. Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy. *J Am Coll Cardiol.* 2005;45:65-9.
157. Rouleau FDR, Merheb M, Geffroy S, et al. Echocardiographic assessment of the interventricular delay of activation and correlation to the QRS width in dilated cardiomyopathy. *PACE* 2001;24:1500-6.
158. Bordachar P, Lafitte S, Reuter S, et al. Echocardiographic parameters of ventricular dyssynchrony validation in patients with heart failure using sequential biventricular pacing. *J Am Coll Cardiol* 2004;44:2157-65.

159. Ansalone G, Giannantoni P, Ricci R, et al. Doppler myocardial imaging in patients with heart failure receiving biventricular pacing treatment. *Am Heart J* 2001;142:881-96.
160. Kindermann M, Frohlig G, Doerr T, Schieffer H. Optimizing the AV delay in DDD pacemaker patients with high degree AV block: mitral valve Doppler versus impedance cardiography. *Pacing Clin Electrophysiol.* 1997;20:2453-62.
161. Breithardt OA, Sinha AM, Schwammenthal E, et al. Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. *J Am Coll Cardiol* 2003;41:765-70.
162. Breithardt OA, Stellbrink C, Kramer AP, et al. Echocardiographic quantification of left ventricular asynchrony predicts an acute hemodynamic benefit of cardiac resynchronization therapy. *J Am Coll Cardiol* 2002;40:536-45.
163. Kim WY, Sogaard P, Mortensen PT, et al. Three dimensional echocardiography documents haemodynamic improvement by biventricular pacing in patients with severe heart failure. *Heart* 2001;85:514-20.
164. Krenning BJ, Szili-Torok T, Voormolen MM, et al. Guiding and optimization of resynchronization therapy with dynamic three-dimensional echocardiography and segmental volume--time curves: a feasibility study. *Eur J Heart Fail.* 2004;6:619-25.
165. Schuster P, Faerstrand S, Ohm O, Martens D, Torkildsen R, Øyehaug O. Feasibility of color tissue velocity imaging for assesment of regional timing of left ventricular longitudinal movement. *Scand Cardiovasc J* 2004;38:39-45.
166. Schuster P, Faerstrand S, Ohm OJ. Color Doppler Tissue Velocity Imaging Demonstrates Significant Asynchronous Regional Left Ventricular Contraction and Relaxation in Patients With Bundle Branch Block and Heart Failure Compared to Control Subjects. *Cardiology* 2004: 102;220-7.
167. Yu CM, Yang H, Lau CP, et al. Regional left ventricle mechanical asynchrony in patients with heart disease and normal QRS duration: implication for biventricular pacing therapy. *PACE.* 2003;26:562-70.
168. Schuster P, Faerstrand S, Ohm OJ. Color Doppler Tissue Velocity Imaging Can Disclose Systolic Left Ventricular Asynchrony Independent of the QRS Morphology in Patients with Severe Heart Failure. *PACE.* 2004;27:460-7.
169. Sogaard P, Kim WY, Jensen HK, et al. Impact of acute biventricular pacing on left ventricular performance and volumes in patients with severe heart failure - A tissue Doppler and three-dimensional echocardiographic study. *Cardiology* 2001;95:173-82.

170. Sogaard P, Egeblad H, Kim WY, et al. Tissue doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy. *J Am Coll Cardiol* 2002;40:723-30.
171. Bax JJ, Molhoek SG, van Erven L, et al. Usefulness of myocardial tissue Doppler echocardiography to evaluate left ventricular dyssynchrony before and after biventricular pacing in patients with idiopathic dilated cardiomyopathy. *Am J Cardiol* 2003;91:94-7.
172. Schuster P, Faerstrand S, Ohm OJ. Colour tissue velocity imaging can show resynchronisation of longitudinal left ventricular contraction pattern by biventricular pacing in patients with severe heart failure. *Heart* 2003;89:859-64.
173. Bax JJ, Marwick TH, Molhoek SG, et al. Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation. *Am J Cardiol* 2003;92:1238-40.
174. Yu CM, Fung WH, Lin H, Zhang Q, Sanderson JE, Lau CP. Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. *Am J Cardiol*. 2003;91:684-8.
175. Breithardt OA, Stellbrink C, Herbots L, et al. Cardiac resynchronization therapy can reverse abnormal myocardial strain distribution in patients with heart failure and left bundle branch block. *J Am Coll Cardiol* 2003;42:486-94.
176. Nelson GS, Berger RD, Fetis BJ, et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. *Circulation*. 2000;102:3053-9.
177. Lindner O, Sorensen J, Vogt J, et al. Cardiac efficiency and oxygen consumption measured with <sup>11</sup>C-acetate PET after long-term cardiac resynchronization therapy. *J Nucl Med*. 2006;47:378-83.
178. Ukkonen H, Beanlands RS, Burwash IG, et al. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. *Circulation*. 2003;107:28-31.
179. Vollmann D, Luthje L, Schott P, Hasenfuss G, Unterberg-Buchwald C. Biventricular pacing improves the blunted force-frequency relation present during univentricular pacing in patients with heart failure and conduction delay. *Circulation*. 2006;113:953-9.
180. Mullens W, Bartunek J, Wilson Tang WH, et al. Early and late effects of cardiac resynchronization therapy on force-frequency relation and

contractility regulating gene expression in heart failure patients. *Heart Rhythm*. 2008;5:52–9.

181. Vanderheyden M, Mullens W, Delrue L, et al. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. *J Am Coll Cardiol*. 2008;51:129–36.

182. Blanc JJ, Etienne Y, Gilard M, et al. Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study. *Circulation*. 1997;96:3273–7.

183. Kass DA, Chen CH, Curry C, et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. *Circulation*. 1999;99:1567–73.

184. Leclercq C, Faris O, Tunin R, et al. Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block. *Circulation*. 2002;106:1760–3.

185. Bordachar P, Lafitte S, Reuter S, et al. Biventricular pacing and left ventricular pacing in heart failure: similar hemodynamic improvement despite marked electromechanical differences. *J Cardiovasc Electrophysiol*. 2004;15:1342–7.

186. Hay I, Melenovsky V, Fetis BJ, et al. Short-term effects of right-left heart sequential cardiac resynchronization in patients with heart failure, chronic atrial fibrillation, and atrioventricular nodal block. *Circulation*. 2004;110:3404–10.

187. St John Sutton MG, Plappert T, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. *Circulation*. 2003;107:1985–90.

188. Steendijk P, Tulner SA, Bax JJ, et al. Hemodynamic effects of long-term cardiac resynchronization therapy: analysis by pressure–volume loops. *Circulation*. 2006;113:1295–304.

189. Sutton MG, Plappert T, Hilpisch KE, Abraham WT, Hayes DL, Chinchoy E. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). *Circulation*. 2006;113:266–72.

190. Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. *Circulation*. 2002;105:438–45.

191. Yu CM, Bleeker GB, Fung JW, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. *Circulation*. 2005;112:1580–6.
192. Stellbrink C, Breithardt OA, Franke A, et al. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. *J Am Coll Cardiol*. 2001;38:1957–65.
193. Schillinger W, Lehnart SE, Prestle J, et al. Influence of SR Ca(2+)-ATPase and Na(+)-Ca(2+)-exchanger on the force-frequency relation. *Basic Res Cardiol*. 1998;93(Suppl 1):38–45.
194. Iyengar S, Haas G, Lamba S, et al. Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy. *J Card Fail*. 2007;13:304–11.
195. Abraham WT, Gilbert EM, Lowes BD, et al. Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. *Mol Med*. 2002;8:750–60.
196. Liao P, Georgakopoulos D, Kovacs A, et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. *Proc Natl Acad Sci USA*. 2001;98:12283–8.
197. Zhang R, Khoo MS, Wu Y, et al. Calmodulin kinase II inhibition protects against structural heart disease. *Nat Med*. 2005;11:409–17.
198. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. *Circ Res*. 1997;81:627–35.
199. D'Ascia C, Cittadini A, Monti MG, Riccio G, Sacca L. Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-alpha expression, and apoptotic death in failing human myocardium. *Eur Heart J*. 2006;27:201–6.
200. Dupuis JM, Kobeissi A, Vitali L, et al. Programming optimal atrioventricular delay in dual chamber pacing using peak endocardial acceleration: comparison with a standard echocardiographic procedure. *Pacing Clin Electrophysiol*. 2003;26:210–13.
201. Butter C, Auricchio A, Stellbrink C, et al. Effect of resynchronization therapy stimulation site on the systolic function of heart failure patients. *Circulation*. 2001;104:3026–9.
202. Guyatt GH, Sullivan MJ, Thompson PJ et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. *Can Med Assoc J*. 1985;132:919–23.
203. Rector TS, Kubo SH, Cohn JN. Patients' Self Assessment of Their Congestive Heart Failure. Part 2: Content, reliability and validity of a new

measure, The Minnesota Living With Heart Failure Questionnaire. *Heart Failure*. 1987; 3:198–209.

204. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6- minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. *JAMA*. 1993;270:1702–7.

205. Myers J, Gullestad L, Vagelos R, et al. Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure. *Ann Intern Med*. 1998; 286–93.

206. Auricchio A, Stellbrink C, Sack S, et al. Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. *J Am Coll Cardiol*. 2002;39:2026–33.

207. Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. *J Am Coll Cardiol*. 2003;42:1454–9.

208. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. *JAMA*. 2003;289:2685–94.

209. Auricchio A, Stellbrink C, Butter C, et al. Pacing Therapies in Congestive Heart Failure II Study Group. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. *J Am Coll Cardiol*. 2003;42:2109–16.

210. Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JGF. Six-minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. *Eur Heart J* 2005;26:778–93.

211. Witte KK, Thackray S, Nikitin NP, Cleland JG, Clark AL. The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure. *Eur J Heart Fail*. 2005;7:612–7.

212. Williams SG, Cooke GA, Wright DJ, Tan LB. Disparate results of ACE inhibitor dosage on exercise capacity in heart failure: a Reappraisal of vasodilator therapy and study design. *Int J Cardiol*. 2001;77:239–45.

213. Reddy P, Dunn AB. The effect of beta-blockers on health-related quality of life in patients with heart failure. *Pharmacotherapy*. 2000;20:679–89.

214. Wolfel EE. Effects of ACE inhibitor therapy on quality of life in patients with heart failure. *Pharmacotherapy*. 1998;18:1323–34.

215. Leclercq C, Walker S, Linde C, et al. MUSTIC Study Group. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. *Eur Heart J*. 2002;23:1780–7.
216. Abraham WT, Young JB, Leon AR, et al. Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverterdefibrillator, and mildly symptomatic chronic heart failure. *Circulation*. 2004;110:2864–8.
217. Beshai JF, Grimm RA, Nagueh SF, et al. RethinQ Study Investigators. Cardiac resynchronization therapy in heart failure with narrow QRS complexes. *N Engl J Med*. 2007; 357:2461–71.
218. Duncan A, Wait D, Gibson D, Daubert JC; MUSTIC (Multisite Stimulation in Cardiomyopathies) trial. Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left ventricular systolic dysfunction and activation disturbances in sinus rhythm: substudy of the MUSTIC trial. *Eur Heart J*. 2003;24:430–41.
219. Braun MU, Rauwolf T, Zerm T, Schulze M, Schnabel A, Strasser RH. Long-term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones. *Heart*. 2005;91:601–5.
220. Fruhwald FM, Fahrleitner-Pammer A, Berger R, et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. *Eur Heart J*. 2007;28:1592–7.
221. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. *JAMA*. 2003;289:730–40.
222. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. *J Cardiovasc Electrophysiol*. 2004;15:1002–9.
223. Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The long-term costeffectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. *Eur Heart J*. 2007;28:42–51.
224. Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med*. 2002;346:877–83.

225. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med.* 2005;352:225–37.
226. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. *Circulation* 2003;107:2920–5.
227. Doshi RN, Daoud EG, Fellows C, et al. PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). *J Cardiovasc Electrophysiol.* 2005;16:1160–5.
228. Brignole M, Gammage M, Puggioni E, et al. Optimal Pacing SITE (OPSITE) Study Investigators. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. *Eur Heart J.* 2005;26:712–22.
229. Molhoek SG, Bax JJ, Bleeker GB, et al. Comparison of response to cardiac resynchronization therapy in patients with sinus rhythm versus chronic atrial fibrillation. *Am J Cardiol.* 2004;94:1506–9.
230. Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. *J Am Coll Cardiol.* 2006;48:734–43.
231. Hoppe UC, Casares JM, Eiskjaer H, et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. *Circulation.* 2006;114:18–25.
232. Egoavil CA, Ho RT, Greenspon AJ, Pavri BB. Cardiac resynchronization therapy in patients with right bundle branch block: analysis of pooled data from the MIRACLE and Contak CD trials. *Heart Rhythm.* 2005;2:611–15.
233. Yu C-M, Fung J W-H, Zhang Q, et al. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. *Circulation.* 2004;110:66–73.
234. Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. *J Am Coll of Cardiol.* 2004; 44:1834–40.
235. Cleland JGF, Daubert JC, Erdmann E, et al; The CARE-HF study Steering Committee and Investigators. The CARE-HF study (CARDiac RESynchronisation in Heart Failure study): rationale, design and end-points. *Eur J Heart Fail* 2001;3:481–9.

236. Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. *Circulation* 2008;117:2608–16.
237. Bleeker GB, Kaandorp TAM, Lamb HJ, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. *Circulation*. 2006;113:969–76.
238. Kerlan JE, Sawhney NS, Waggoner AD, et al. Prospective comparison of echocardiographic atrioventricular delay optimization methods for cardiac resynchronization therapy. *Heart Rhythm*. 2003; 3:148–54.
239. Sawhney NS, Waggoner AD, Garhwal S, Chawla MK, Osborn J, Faddis MN. Randomized prospective trial of atrioventricular delay programming for cardiac resynchronization therapy. *Heart Rhythm*. 2004;1:562–7.
240. Morales M-A, Startari U, Panchetti L, Rossi A, Piacenti M. Atrioventricular Delay Optimization by Doppler-Derived Left Ventricular dP/dt Improves 6-Month Outcome of Resynchronized Patients. *PACE*. 2006; 29:564–8.
241. Sogaard P, Egeblad H, Pedersen AK, et al. Sequential versus simultaneous biventricular resynchronization for severe heart failure: evaluation by tissue Doppler imaging. *Circulation*. 2002;106:2078–84.
242. RK Rao, UN Kumar, J Schafer, E Vilorio, D Delurgio, E Foster. Reduced ventricular volumes and improved systolic function with cardiac resynchronization therapy: a randomized trial comparing simultaneous biventricular pacing, sequential biventricular pacing, and left ventricular pacing. *Circulation*. 2007;115:2136–44.
243. Boriani G, Müller CP, Seidl KH, et al. Resynchronization for the Hemodynamic Treatment for Heart Failure Management II Investigators. Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. The Resynchronization for the Hemodynamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study. *Am Heart J*. 2006;151:1050–8.
244. Colucci WS, Ribeiro JP, Rocco MB, et al. Impaired chronotropic response to exercise in patients with congestive heart failure. Role of postsynaptic  $\beta$ -adrenergic desensitization. *Circulation*. 1989;80:314–23.
245. Auricchio A, Klein H, Tockman B, et al. Transvenous biventricular pacing for heart failure: can the obstacles be overcome? *Am J Cardiol*. 1999;83:136–42.
246. Ansalone G, Giannantoni P, Ricci R, Trambaiolo P, Fedele F, Santini M. Doppler myocardial imaging to evaluate the effectiveness of pacing sites in patients receiving biventricular pacing. *J Am Coll Cardiol*. 2002; 39:489–99.

247. Singh JP, Houser S, Heist EK, Ruskin JN. The coronary venous anatomy: a segmental approach to aid cardiac resynchronization therapy. *J Am Coll Cardiol*. 2005;46:68–74.
248. Chou CC, Kim DT, Fishbein MC, Chen PS. Marshall bundle and the valve of Vieussens. *J Cardiovasc Electrophysiol*. 2003;14:1254–9.
249. Meisel E, Pfeiffer D, Engelmann L, et al. Investigation of coronary venous anatomy by retrograde venography in patients with malignant ventricular tachycardia. *Circulation*. 2001;104:442–7.
250. Karaca M, Bilge O, Dinckal MH, Ucerler H. The anatomic barriers in the coronary sinus: implications for clinical procedures. *J Interv Card Electrophysiol*. 2005;14:89–94.
251. Giudici MC, Paul DL, Bontu P, Barold SS. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. *Pacing Clin Electrophysiol*. 2004;27:358–60.
252. Fox DJ, Davidson NC, Royle M, et al. Safety and acceptability of implantation of internal cardioverter-defibrillators under local anesthetic and conscious sedation. *Pacing Clin Electrophysiol*. 2007;30:992–7.
253. Klug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. *Circulation*. 2007;116:1349–55.
254. Bertaglia E, Zerbo F, Zardo S, Barzan D, Zoppo F, Pascotto P. Antibiotic prophylaxis with a single dose of cefazolin during pacemaker implantation: incidence of long-term infective complications. *Pacing Clin Electrophysiol*. 2006;29:29–33.
255. Leon AR, Delurgio DB, Mera F. Practical approach to implanting left ventricular pacing leads for cardiac resynchronization. *J Cardiovasc Electrophysiol*. 2005;16:100–5.
256. Sticherling C, Chough SP, Baker RL, et al. Prevalence of central venous occlusion in patients with chronic defibrillator leads. *Am Heart J*. 2001;141:813–16.
257. Corcoran SJ, Lawrence C, McGuire MA. The valve of Vieussens: an important cause of difficulty in advancing catheters into the cardiac veins. *J Cardiovasc Electrophysiol*. 1999;10:804–8.
258. Jongbloed MR, Lamb HJ, Bax JJ, et al. Noninvasive visualization of the cardiac venous system using multislice computed tomography. *J Am Coll Cardiol*. 2005;45:749–53.
259. Chiribiri A, Kelle S, Gotze S, et al. Visualization of the cardiac venous system using cardiac magnetic resonance. *Am J Cardiol*. 2008;101:407–12.
260. Leon AR. New tools for the effective delivery of cardiac resynchronization therapy. *J Cardiovasc Electrophysiol*. 2005;16S1:S42–7.

261. Rivero-Ayerza M, Thornton AS, Theuns DA, et al. Left ventricular lead placement within a coronary sinus side branch using remote magnetic navigation of a guidewire: a feasibility study. *J Cardiovasc Electrophysiol*. 2006;17:128–33.
262. Rivero-Ayerza M, van Belle Y, Mekel J, Jordaens LJ. Left ventricular lead implantation assisted by magnetic navigation in a patient with a persistent left superior vena cava. *Int J Cardiol*. 2007;116:E15–7.
263. Burkhardt JD, Wilkoff BL. Interventional electrophysiology and cardiac resynchronization therapy: delivering electrical therapies for heart failure. *Circulation*. 2007;115:2208–20.
264. Vannan MA, Pedrizzetti G, Li P, et al. Effect of cardiac resynchronization therapy on longitudinal and circumferential left ventricular mechanics by velocity vector imaging: description and initial clinical application of a novel method using high-frame rate B-mode echocardiographic images. *Echocardiography*. 2005;22:826–30.
265. Ammann P, Sticherling C, Kalusche D, et al. An electrocardiogram-based algorithm to detect loss of left ventricular capture during cardiac resynchronization therapy. *Ann Intern Med*. 2005;142:968–73.
266. Hoffmeister P, Chaudhry GM, Orlov MV, Shukla G, Haffajee CI. Sheathless implantation of permanent coronary sinus-LV pacing leads. *Pacing Clin Electrophysiol*. 2006;29:117–23.
267. Alonso C, Leclercq C, d'Allonnes FR, et al. Six year experience of transvenous left ventricular lead implantation for permanent biventricular pacing in patients with advanced heart failure: technical aspects. *Heart*. 2001;86:405–10.
268. Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) Trial. *Circulation* 2011;123:1159–66.
269. Healey JS, Hohnloser SH, Exner DV, et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). *Circ Heart Fail* 2012;5:566-70.
270. Linde C, Abraham WT, Gold MR, Daubert C; REVERSE Study Group. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVERses Remodeling in Systolic Left vEntricular Dysfunction) study. *J Am Coll Cardiol* 2010;56:1826-31.
271. Arshad A, Moss AJ, Foster E, et al., Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter

- Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. *J Am Coll Cardiol* 2011;57:813-20.
272. Brandon K. Fornwalt, William W. Sprague, Patrick BeDell, et al. Agreement Is Poor Among Current Criteria Used to Define Response to Cardiac Resynchronization Therapy. *Circulation*. 2010;121:1985-91.
273. Gras D, Leclercq C, Tang AS, et al. Cardiac resynchronization therapy in advanced heart failure the multicenter InSync clinical study. *Eur J Heart Fail*. 2002;4:311-20.
274. Kühlkamp V. Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy. *J Am Coll Cardiol*. 2002;39:790-7.
275. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. *J Am Coll Cardiol*. 2008;52:1834-43.
276. Alan D. Waggoner, Mitchell N. Faddis; Marye J. Gleva, Lisa de las Fuentes, Víctor G. Dávila-Román. Improvements in Left Ventricular Diastolic Function After Cardiac Resynchronization Therapy Are Coupled to Response in Systolic Performance. *J Am Coll Cardiol*. 2005;46:2244-9.
277. Doltra A, Bijnens B, Tolosana JM, et al. Effect of cardiac resynchronization therapy on left ventricular diastolic function: implications for clinical outcome. *J Card Fail*. 2013 Dec;19:795-801.
278. Boriani G, Valzania C, Fallani F, et al. Effects of cardiac resynchronization therapy on diastolic function: evaluation by radionuclide angiography. *Pacing Clin Electrophysiol*. 2007;30:S43-6.
279. Di Biase L, Auricchio A, Mohanty P, et al. Impact of cardiac resynchronization therapy on the severity of mitral regurgitation. *Europace*. 2011;13:829-38.
280. Jalal Kheirkhah, Vahid Toulabi, Hassan Moladoust, et al. Cardiac Resynchronization Therapy: Effects on Mitral Regurgitation in Heart Failure Patients. *American Journal of Cardiovascular Disease Research*. 2013;1:12-5.
281. Jorge Solis, David McCarty, Robert A. Levine, et al. Mechanism of Decrease in Mitral Regurgitation After Cardiac Resynchronization Therapy. *Circ Cardiovasc Imaging*. 2009; 2: 444-50.
282. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac

Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2008;51:2085–105.

283. Tang AS, Ross H, Simpson CS, et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. *Can J Cardiol* 2005;21(suppl A):11A–8.

284. Gorcsan J III. Role of echocardiography to determine candidacy for cardiac resynchronization therapy. *Curr Opin Cardiol* 2008;23:16–22.

285. Yu CM, Fung JWH, Zhang Q, Sanderson JE. Understanding nonresponders of cardiac resynchronization therapy—current and future perspectives. *J Cardiovasc Electrophysiol* 2005;16:1117–24.

286. L. Gabrielli, G. Marincheva, B. Bijnens, et.al. Septal flash predicts cardiac resynchronization therapy response in patients with permanent atrial fibrillation. *Europace*. 2014;16:1342-9.

287. Adam R. Bryant, Stephen B. Wilton, Michael P. Lai, Derek V. Exner. Association between QRS duration and outcome with cardiac resynchronization therapy: A systematic review and meta-analysis. *Journal of Electrocardiology* 2013;46:147–55.

288. Miriam Shanks, Victoria Delgado, Arnold C.T. Ng, et al. Clinical and echocardiographic predictors of nonresponse to cardiac resynchronization therapy. *Am Heart J* 2011;161:552-7.

289. Saxon LA, Bristow MR, Boehmer J, et al., Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. *Circulation* 2006;114:2766-72.

290. Jason S. Chinitz, Andre d’Avila, et al. Cardiac Resynchronization Therapy: Who Benefits? Review. *Annals of Global Health* 2014;80:61-8.

291. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. *Circulation*. 2007;115:204-12.

292. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. *J Am Coll Cardiol*. 2012;60:1297-313.

293. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. *Eur Heart J*. 2010;31:2677-87.

294. S. Kirubakaran, A. Ladwiniec, A. Arujuna, et al. Male gender and chronic obstructive pulmonary disease predict a poor clinical response in patients undergoing cardiac resynchronisation therapy. *Int J Clin Pract.* 2011;65:281–8.
295. Theuns DA, Schaer BA, Soliman OI, et al. The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. *Europace* 2011;13:62-9.
296. Frederik H. Verbrugge, Matthias Dupont, Maximo Rivero-Ayerza, et al. Comorbidity Significantly Affects Clinical Outcome After Cardiac Resynchronization Therapy Regardless of Ventricular Remodeling. *J Cardiac Fail* 2012;18:845-53.
297. Ulas Höke, Joep Thijssen, Rutger J. van Bommel. Influence of Diabetes on Left Ventricular Systolic and Diastolic Function and on Long-Term Outcome After Cardiac Resynchronization Therapy. *Diabetes Care.* 2013;36:985–91.
298. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. *Circulation* 2006;113:671–8.
299. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 2003;41:1–12.
300. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998;32:S112–9.
301. Goldenberg I, Moss AJ, McNitt S, et al. Relations among renal function, risk of sudden cardiac death and benefit of the implanted cardiac defibrillator in patients with ischemic LV dysfunction. *Am J Cardiol* 2006;98:485–90.
302. Adelstein EC, Shalaby A, Saba S. Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency. *Pacing Clin Electrophysiol* 2010;33:850–9.
303. Fung JWH, Szeto CC, Chan JYS, et al. Prognostic value of renal function in patients with cardiac resynchronization therapy. *Int J Cardiol* 2007;122:10–6.
304. Heywood JT, Fonarow GC, Yancy CW, et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. *Am J Cardiol* 2010;105:1140–6.

305. Sakhuja R, Keebler M, Lai TS, et al. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. *Am J Cardiol* 2009;103:735-41.
306. Cuculich PS, Sanchez JM, Kerzner R, et al. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. *Pacing Clin Electrophysiol* 2007;30:207-13.
307. Jonathan C. Hsu, Scott D. Solomon, Mikhail Bourgoun et al. Predictors of Super-Response in the MADIT-CRT Trial. *J Am Coll Cardiol* 2012;59:2366-73.
308. Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. *Arch Intern Med* 2005;165:55-61.
309. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. *Circulation*. 2010;122:2022-30.
310. Bleeker GB, Schalij MJ, Molhoek SG, et al. Frequency of left ventricular dyssynchrony in patients with heart failure and a narrow QRS complex. *Am J Cardiol*. 2005;95:140-2.
311. Thibault B, Harel F, Ducharme A, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. *Circulation* 2013;127: 873-81.
312. Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. *N Engl J Med* 2013;369:1395-405.
313. Strauss DG, Selvester RH, Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. *Am J Cardiol*. 2010;107:927-34.
314. Gervais R, Leclercq C, Shankar A, et al. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. *Eur J Heart Fail*. 2009;11:699-705.
315. Dupont M, Rickard J, Baranowski B, et al. Differential Response to Cardiac Resynchronization Therapy and Clinical Outcomes According to QRS Morphology and QRS Duration. *J Am Coll Cardiol* 2012;60:592-8.
316. Gold MR, Thebault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. *Circulation* 2012;126:822-9.

317. Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang JC. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. *Arch Intern Med* 2011;171:1454-62.
318. Yusuf J, Agrawal DK, Mukhopadhyay S, et al. Fragmented narrow QRS complex: predictor of left ventricular dyssynchrony in non-ischemic dilated cardiomyopathy. *Indian Heart J* 2013;65:172-9.
319. Tigen K, Karaahmet T, Gurel E, et al. The utility of fragmented QRS complexes to predict significant intraventricular dyssynchrony in nonischemic dilated cardiomyopathy patients with a narrow QRS interval. *Can J Cardiol* 2009;25:517-22.
320. Celikyurt U, Agacdiken A, Sahin T, et al. Relationship between fragmented QRS and response to cardiac resynchronization therapy. *J Interv Card Electrophysiol* 2012;35:337-42.
321. Celikyurt U, Agacdiken A, Sahin T, et al. Number of leads with fragmented QRS predicts response to cardiac resynchronization therapy. *Clin Cardiol* 2013;36:36-9.
322. Strauss DG, Selvester RH. The QRS complex, a biomarker that “images” the heart: QRS scores to quantify myocardial scar in the presence of normal and abnormal ventricular conduction. *J Electrocardiol* 2009; **42**: 85 – 96.
323. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. *Circulation*. 2003;107:2920-5.
324. Mullens W, Grimm RA, Verga T, et al., Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. *J Am Coll Cardiol* 2009;53:765-73.
325. Ritter P, Padeletti L, Gillio-Meina L, Gaggini G. Determination of the optimal atrioventricular delay in DDD pacing. Comparison between echo and peak endocardial acceleration measurements. *Europace* 1999;1:126-30.
326. Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. *Heart Rhythm* 2011;8:1469-75.
327. Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. *Heart Rhythm* 2011;8:1088-94.
328. Gasparini M, Auricchio A, Metra M, et al., Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing

atrio-ventricular junction ablation in patients with permanent atrial fibrillation. *Eur Heart J* 2008;29:1644-52.

329. Kamath GS, Cotiga D, Koneru JN, et al. The utility of 12-lead Holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. *J Am Coll Cardiol* 2009;53:1050-5.

330. Woo GW, Petersen-Stejskal S, Johnson JW, Conti JB, Aranda JA Jr., Curtis AB. Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study. *J Interv Card Electrophysiol.* 2005;12:107-13.

331. D. Rinkuniene, S. Bucyte, K. Ceseviciute et al. Predictors of positive response to cardiac resynchronization therapy. *BMC Cardiovascular Disorders* 2014,14: 55-63.

332. Díaz-Infante E, Mont L, Leal J, et al. Predictors of lack of response to resynchronization therapy. *Am J Cardiol* 2005;95:1436–40.

333. Ghio S, Freemantle N, Scelsi L, et al. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. *Eur J Heart Fail* 2009;11:480–8.

334. Reuter S, Garrigue S, Barold SS, et al. Is the outcome of cardiac resynchronization therapy related to the underlying etiology? *Pacing Clin Electrophysiol* 2003;26:175–80.

335. Reuter S, Garrigue S, Barold SS, et al. Comparison of characteristics in responders versus nonresponders with biventricular pacing for drug-resistant congestive heart failure. *Am J Cardiol* 2002;89:346–50.

336. Molhoek SG, Bax JJ, Van Erven L, et al. Comparison of benefits from cardiac resynchronization therapy in patients with ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy. *Am J Cardiol* 2004;93:860–3.

337. Mele D, Agricola E, Galderisi M, et al. Echocardiographic myocardial scar burden predicts response to cardiac resynchronization therapy in ischemic heart failure. *J Am Soc Echocardiogr* 2009;22:702–8.

338. Riedlbauchova L, Brunken R, Jaber WA, et al. The impact of myocardial viability on the clinical outcome of cardiac resynchronization therapy. *J Cardiovasc Electrophysiol* 2009;20:50–7.

339. Tang AS, Ellenbogen KA. A futuristic perspective on clinical studies of cardiac resynchronization therapy for heart failure patients. *Curr Opin Cardiol* 2006;21:78-82.

340. Yu CM, Gorcsan J III, Bleeker GB, et al. Usefulness of tissue Doppler velocity and strain dyssynchrony for predicting left ventricular reverse remodeling response after cardiac resynchronization therapy. *Am J Cardiol* 2007;100:1263–70.

341. Sanderson JE. Echocardiography for cardiac resynchronization therapy selection: fatally flawed or misjudged? *J Am Coll Cardiol* 2009;53:1960—4.
342. Bax JJ, Goresan III J. Echocardiography and noninvasive imaging in cardiac resynchronization therapy: results of the PROSPECT (Predictors of Response to Cardiac Resynchronization Therapy) study in perspective. *J Am Coll Cardiol* 2009;53:1933—43.
343. Yu CM, Sanderson JE, Goresan III J. Echocardiography, dyssynchrony, and the response to cardiac resynchronization therapy. *Eur Heart J* 2010;31:2326—37.
344. Yu CM, Bax JJ, Goresan III J. Critical appraisal of methods to assess mechanical dyssynchrony. *Curr Opin Cardiol* 2009;24:18—28.
345. Qing Zhang, Cheuk Man. Is mechanical dyssynchrony still a major determinant for responses after cardiac resynchronization therapy? Review. *Journal of Cardiology* 2011;57:239-48.
346. van Bommel RJ, Bax JJ, Abraham WT, et al. Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis. *Eur Heart J* 2009;30:2470—7.
347. Lim P, Buakhamsri A, Popovic ZB, et al. Longitudinal strain delay index by speckle tracking imaging: a new marker of response to cardiac resynchronization therapy. *Circulation* 2008;118:1130-7.
348. Zhang Q, vanBommel RJ, Fung JW, et al. Tissue Doppler velocity is superior to strain imaging in predicting long-term cardiovascular events after cardiac resynchronization therapy. *Heart* 2009;95:1085-90.
349. Lafitte S, Reant P, Zaroui A, et al. Validation of an echocardiographic multiparametric strategy to increase responders patients after cardiac resynchronization: a multicentre study. *Eur Heart J* 2009;30:2880-7.
350. van Bommel RJ, Ypenburg C, Borleffs CJ, et al. Value of tissue Doppler echocardiography in predicting response to cardiac resynchronization therapy in patients with heart failure. *Am J Cardiol* 2010;105:1153-8.
351. Oyenuga O, Hara H, Tanaka H, et al. Usefulness of echocardiographic dyssynchrony in patients with borderline QRS duration to assist with selection for cardiac resynchronization therapy. *JACC Cardiovasc Imaging* 2010;3:132-40.
352. van Bommel RJ, Borleffs CJ, Ypenburg C, et al. Morbidity and mortality in heart failure patients treated with cardiac resynchronization therapy: influence of preimplantation characteristics on long-term outcome. *Eur Heart J* 2010;31:2783-90.
353. van Bommel RJ, Tanaka H, Delgado V, et al. Association of intraventricular mechanical dyssynchrony with response to cardiac

resynchronization therapy in heart failure patients with a narrow QRS complex. *Eur Heart J* 2010;31:3054-62.

354. Gorcsan III J, Oyenuga O, Habib PJ, et al. Relationship of echocardiographic dyssynchrony to long-term survival after cardiac resynchronization therapy. *Circulation* 2010;122:1910-8.

355. Tanaka H, Nesser HJ, Buck T, et al. Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study. *Eur Heart J* 2010;31:1690-700.

356. Ascione L, Iengo R, Accadia M, et al. A radial global dyssynchrony index as predictor of left ventricular reverse remodeling after cardiac resynchronization therapy. *Pacing Clin Electrophysiol.* 2008;31:819-27.

357. Bertola B, Rondano E, Sulis M, et al. Cardiac dyssynchrony quantitated by time-to-peak or temporal uniformity of strain at longitudinal, circumferential, and radial level: implications for resynchronization therapy. *J Am Soc Echocardiogr.* 2009;22:665-71.

358. Bordachar P, Lafitte S, Reant P, et al. Low value of simple echocardiographic indices of ventricular dyssynchrony in predicting the response to cardiac resynchronization therapy. *Eur J Heart Fail.* 2010;12:588-92.

359. Delgado V, van Bommel RJ, Bertini M, et al. Relative merits of left ventricular dyssynchrony, left ventricular lead position, and myocardial scar to predict long-term survival of ischemic heart failure patients undergoing cardiac resynchronization therapy. *Circulation* 2011;123:70-8.

360. Foley PW, Chalil S, Khadjooi K, et al. Effects of cardiac resynchronization therapy in patients unselected for mechanical dyssynchrony. *Int J Cardiol* 2010;143:51-6.

361. Inden Y, Ito R, Yoshida N, et al. Combined assessment of left ventricular dyssynchrony and contractility by speckled tracking strain imaging: a novel index for predicting responders to cardiac resynchronization therapy. *Heart Rhythm* 2010;7:655-61.

362. Ypenburg C, van Bommel RJ, Borleffs CJ, et al. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. *J Am Coll Cardiol* 2009;53:483-90.

363. Zhang Q, Yip GW, Chan YS, et al. Incremental prognostic value of combining left ventricular lead position and systolic dyssynchrony in predicting long-term survival after cardiac resynchronization therapy. *Clin Sci.* 2009;117:397-404.

364. Zhang Q, Fung JW, Chan JY, et al. Difference in long-term clinical outcome after cardiac resynchronization therapy between ischemic and non-ischemic etiologies of heart failure. *Heart* 2009;95:113-8.
365. Richardson M, Freemantle N, Calvert MJ, Cleland JG, Tavazzi L. Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. *Eur Heart J* 2007;28:1827-34.
366. Gradaus R, Stuckenberg V, Loher A, et al. Diastolic filling pattern and left ventricular diameter predict response and prognosis after cardiac resynchronisation therapy. *Heart* 2008;94:1026-31.
367. Achilli A, Peraldo C, Sassara M, et al. Prediction of response to cardiac resynchronization therapy: the selection of candidates for CRT (SCART) study. *Pacing Clin Electrophysiol* 2006, 29:S11-9.
368. Erberto Carluccio, Paolo Biagioli, Gianfranco Alunni, et al. Presence of Extensive LV Remodeling Limits the Benefits of CRT in Patients With Intraventricular Dyssynchrony. *J Am Coll Cardiol Img.* 2011;4:1067-76.
369. Agacdiken Agir A, Celikyurt U, Sahin T, et al. What is the lowest value of left ventricular baseline ejection fraction that predicts response to cardiac resynchronization therapy? *Med Sci Monit.* 2014;20:1641-6.
370. Cheuk-Man Yu, Qing Zhang, Gabriel Wai-Kwok Yip, et al. Are Left Ventricular Diastolic Function and Diastolic Asynchrony Important Determinants of Response to Cardiac Resynchronization Therapy? *Am J Cardiol* 2006;98:1083-7.
371. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease. Part II: pathophysiology, clinical importance, and management of right ventricular failure. *Circulation* 2008;117:1717-31.
372. Polak JF, Holman BL, Wynne J, Colucci WS. Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. *J Am Coll Cardiol* 1983;2:217-24.
373. Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. *J Am Coll Cardiol* 1995;25:1143-53.
374. De Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. *J Am Coll Cardiol* 1998;32:948-54.
375. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. *J Am Coll Cardiol* 2001;37:183-8.

376. Roberto M. Lang, Michelle Bierig, Richard B. Devereux, et al. Recommendations for chamber quantification. *Eur J Echocardiography* 2006;7:79-108
377. Samad B.A., Alam M., Jensen-Urstad K. Prognostic impact of right ventricular involvement as assessed by tricuspid annular motion in patients with acute myocardial infarction. *Am J Cardiol* 2002;90:778-81.
378. Field ME, Solomo SD, Lewis EF, et al. Right ventricular dysfunction and adverse outcome in patients with advanced heart failure. *J Card Fail* 2006;12:616–20.
379. Scuteri L, Rordorf R, Marsan NA, et al. Relevance of echocardiographic evaluation of right ventricular function in patients undergoing cardiac resynchronization therapy. *PACE* 2009;32:1040–9.
380. Ogunyankin KO, Puthumana JJ. Effect of cardiac resynchronization therapy on right ventricular function. *Curr Opin Cardiol* 2010;22:464–8.
381. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. *Circulation* 2008;117:1436–48.
382. Ghio S, Recusani F, Klersy C, et al. Prognostic usefulness of tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. *Am J Cardiol* 2000;85:837–42.
383. Magnus Edner, Margareta Ringl, Peter Henriksson. Pre-implant right ventricular function might be an important predictor of the response to cardiac resynchronization therapy. *Cardiovascular Ultrasound* 2011;9:28-4.
384. Tabereaux PB, Doppalapudi H, Kay GN, Mcelderry T, Plumb VJ, Epstein AE. Limited response to cardiac resynchronization therapy in patients with concomitant right ventricular dysfunction. *J Cardiovasc Electrophysiol* 2009;19:1-5.
385. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. *J Am Soc Echocardiogr* 1996;9:838–47.
386. Dongmei Wang, Yaling Han, Hongyun Zang, et al. Prognostic effects of pulmonary hypertension in patients undergoing cardiac resynchronization therapy. *J Thorac Dis.* 2010; 2: 71–5.
387. Chatterjee NA, Upadhyay GA, Singal G, et al. Pre-Capillary Pulmonary Hypertension and Right Ventricular Dilation Predict Clinical Outcome in Cardiac Resynchronization Therapy. *JCHF.* 2014;2:230-7.
388. Victoria Delgado, Jeroen J. Bax. Cardiac resynchronization therapy: relevance of right ventricular function evaluation. *Europace* 2010;12:311-2.

389. K.M. Stein, K.A. Ellenbogen, M.R. Gold, et al. Smart Delay determined AV optimization: a comparison of AV delay methods used in cardiac resynchronization therapy (SMART-AV): rationale and design, *PACE* 2010;1:54–63.
390. K.A. Ellenbogen, M.R. Gold, T.E. Meyer, et al. Primary results from the Smart Delay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy, *Circulation* 2010;122:2660–8.
391. Abraham WT, Gras D, Yu CM, Guzzo L, Gupta MS; FREEDOM Steering Committee. Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: the Frequent Optimization Study Using the QuickOpt Method (FREEDOM) trial. *Am Heart J.* 2010;159:944-8.
392. G. Boriani, M. Biffi, C.P. Muller, et al. A prospective randomized evaluation of VV delay optimization in CRT-D recipients: echocardiographic observations from the RHYTHM III CD study. *PACE* 2009;32:S120–5.
393. D.O. Martin, B. Lemke, D. Birnie, et al. Adaptive CRT SI. Investigation of a novel algorithm for synchronized left ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial, *Heart Rhythm* 2012;9:1807–14.
394. Gasparini M, Mantica M, Galimberti P, et al. Is the left ventricular lateral wall the best lead implantation site for cardiac resynchronization therapy? *Pacing Clin Electrophysiol.* 2003;26:162-8.
395. Wyman BT, Hunter WC, Prinzen FW, Faris OP, McVeigh ER. Effects of single- and biventricular pacing on temporal and spatial dynamics of ventricular contraction. *Am J Physiol* 2002;282:H372–9.
396. Saxon LA, Olshansky B, Volosin K, et al. Influence of left ventricular lead location on outcomes in the COMPANION study. *J Cardiovasc Electrophysiol.* 2009;20:764–8.
397. Dekker AL, Phelps B, Dijkman B, et al. Epicardial left ventricular lead placement for cardiac resynchronization therapy: optimal pace site selection with pressure-volume loops. *J Thorac Cardiovasc Surg.* 2004;127:1641–7.
398. Ypenburg C, van Bommel RJ, Delgado V, et al. Optimal left ventricular lead position predicts reverse remodeling and survival after cardiac resynchronization therapy. *J Am Coll Cardiol.* 2008;52:1402–9.
399. Derval N, Steendijk P, Gula LJ, et al. Optimizing hemodynamics in heart failure patients by systematic screening of left ventricular pacing sites: the

lateral left ventricular wall and the coronary sinus are rarely the best sites. *J Am Coll Cardiol.* 2010;55:566–75.

400. Bleeker GB, Schalij MJ, Van Der Wall EE, Bax JJ. Postero-lateral scar tissue resulting in non-response to cardiac resynchronization therapy. *J Cardiovasc Electrophysiol.* 2006;17:899–901.

401. Merchant FM, Heist EK, Nandigam KV, et al. Interlead distance and left ventricular lead electrical delay predict reverse remodeling during cardiac resynchronization therapy. *Pacing Clin Electrophysiol.* 2010;33:575–82.

402. Goldenberg I, Moss AJ, Hall WJ, et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). *Circulation* 2011;124:1527–36.

403. Shen X, Nair CK, Aronow WS, et al. A patient selection score for cardiac resynchronization therapy. *Echocardiography.* 2011 ;28(2):188-95.

404. Kang Y, Cui J, Li L, et al. A new score system for prediction response to cardiac resynchronization therapy. *Cardiol J.* Epub ahead of print. doi: 10.5603/CJ.a2014.0089.

## المخلص العربي

إن فشل القلب هو واحد من أهم أسباب المراضة والوفيات في العالم و يصاحبه في كثير من الأحيان تباطؤ استحثاث البطين الأيسر الذي يتضح من خلال إطالة مدة إشارة البطين (QRS) في تخطيط القلب الكهربى و الذى يوجد تقريبا في ربع أو ثلث مرضى فشل القلب. تعتبر إطالة مدة إشارة البطين (QRS) فى تخطيط القلب الكهربى مؤشرا كبيرا على تفاقم الخلل الانقباضى للبطين الأيسر و كما تنتبأ بالنتائج الأكثر سوءا على المدى القريب و البعيد في المرضى الذين يعانون من فشل القلب. وقد استخدم العلاج بزرع جهاز إعادة مزمنة القلب بنجاح لتحسين ضعف التنسيق الكهربائى والميكانيكى في مرضى فشل القلب مما نتج عنه تحسين معدلات الاعتلال والوفيات فى هؤلاء المرضى. ويقدر عموما أن 30-40% من المرضى لا يستجيبون للعلاج عن طريق زرع جهاز إعادة مزمنة القلب بالصورة المرجوة برغم مطابقتهم لمتطلبات زرع هذا الجهاز الواردة فى المبادئ التوجيهية الأمريكية و الأوروبية لعلاج مرضى فشل القلب. لذلك فإن كيفية التنبؤ بالمرضى الذين يستجيبون لزرع جهاز إعادة مزمنة القلب يبقى سؤال مهم ولم يتم الرد عليه إلى حد كبير.

الهدف من هذه الدراسة هو تقييم وتحديد أفضل مؤشرات الاستجابة للعلاج بزرع جهاز إعادة مزمنة القلب.

تمت الدراسة على المرضى الذين يعانون من فشل القلب و ضعف البطين الأيسر بنسبة  $\geq 35\%$  المقرر لهم العلاج بجهاز إعادة مزمنة القلب. وقد خضع المرضى بعد موافقتهم الكتابية للآتى:

أخذ التاريخ المرضى السابق و الفحص الاكلينيكي و رسم تخطيط القلب الكهربى و فحص القلب بموجات صدى الصوت وتصوير الأوعية التاجية في المرضى الذين يشتبه اصابتهم بقصور الاوعية التاجية.

تم تقييم استجابة المرضى للعلاج بجهاز إعادة مزمنة القلب بعد 6-12 شهرا من تركيب الجهاز معتمدا على الاستجابة الاكلينيكية (التحسن فى درجة ضيق التنفس بمقدار درجة او أكثر وفقا لتصنيف جمعية القلب بنيويورك) و فحص القلب باستخدام موجات صدى الصوت (تقليل حجم القلب فى نهاية الإنقباض بمقدار 15% او أكثر) مقارنة بما كان عليه المريض قبل تركيب الجهاز . وقد تم تحليل البيانات باستخدام برنامج SPSS للإحصاء.

النتائج: شملت الدراسة مائة وسبعين مريضا (متوسط أعمارهم  $68.8 \pm 9.7$  سنوات، 38 من الإناث و 132 من الذكور).

قبل عملية زرع جهاز إعادة مزمنة القلب: كان السبب فى ضعف عضلة القلب هو اعتلال عضلة القلب التوسعى فى 91 مريض و اعتلال عضلة القلب الإقفاري فى 79 مريضا. قبل زرع الجهاز كان المرضى يعانون من ضيق التنفس بحسب تصنيف جمعية القلب بنيويورك من الدرجة الثانية فى 23 مريضا و من الدرجة الثالثة فى مريضا 136 و من الدرجة الرابعة فى 11 مريضا. كان متوسط

مدة إشارة البطين QRS =  $145 \pm 25$  ميلي ثانية. اتضح وجود انسداد بالفرع الضفيري الأيسر بتخطيط القلب الكهربى فى 55.3% من المرضى. أثناء زرع الجهاز كانت ضربات القلب منتظمة وفقا للنظام الجيب أذينى فى 147 مريض (86.5%) فى حين أن 23 مريض (13.5%) كانوا يعانون من وجود ذبذبة أذينية. وكان متوسط البعد الداخلى للبطين الأيسر فى نهاية الانبساط  $67.6 \pm 9$  مم و متوسط البعد الداخلى للبطين الأيسر فى نهاية الانقباض كان  $55.7 \pm 10$  مم، وكان متوسط حجم البطين الأيسر فى نهاية الانبساط  $205.7 \pm 66$  مل و متوسط حجم البطين الأيسر فى نهاية الانقباض  $148.3 \pm 56$  مل. وكان متوسط نسبة طرد البطين الأيسر  $28.3 \pm 7.7$ %. كان متوسط البعد الداخلى للبطين الأيمن فى نهاية الانبساط  $34.15 \pm 5.9$  مم وكان متوسط ذروة حركة حلقة الصمام ثلاثى الشرف الانقباضية =  $18.16 \pm 3.8$  مم.

بعد زرع الجهاز: تحققت الاستجابة لزرع جهاز إعادة مزامنة القلب فى 114 مريضا (67.1%). وارتبط زرع جهاز إعادة مزامنة القلب مع تحسن فى حجم البطين الأيسر ومهامه وعلامات سوء التزامن فى البطين الأيسر. وارتبط أيضا زرع جهاز إعادة مزامنة القلب مع تحسن فى درجة ضيق التنفس و زيادة فى المسافة المقطوعة خلال 6 دقائق سيرا على الأقدام و تحسن فى وظيفية انبساط البطين الأيسر وتقليل نسبة أرتجاع الدم بالصمام ثنائى الشرف (المتراالى).

مقارنة المستجيبين للجهاز مع غير المستجيبين: مدة إشارة البطين QRS فى تخطيط القلب الكهربى عند بداية الدراسة كانت أطول فى المستجيبين. تميز المستجيبون للجهاز أيضا بالمقارنة بغير المستجيبون عند بداية الدراسة بانخفاض مؤشر كتلة الجسم وانخفاض مستوى الكرياتينين فى الدم و صغر البعد الداخلى للبطين الأيمن و ارتفاع قيمة متوسط ذروة حركة حلقة الصمام ثلاثى الشرف الانقباضية.

### مؤشرات الاستجابة لزرع جهاز إعادة مزامنة القلب:

فى التحليل وحيد المتغير تبين أن مؤشرات الاستجابة لزرع الجهاز هم كلا مما يلى:

الجنس الأنثوي وعدم وجود مرض الانسداد الرئوى المزمن و عدم وجود تاريخ مرضى وأمراض الكلى و زيادة مدة إشارة البطين QRS فى تخطيط القلب الكهربى بمقدار  $150$  ميلي ثانية أو أكثر و وجود انسداد بالفرع الضفيري الأيسر بتخطيط القلب الكهربى و انتظام ضربات القلب وفقا للنظام الجيب أذينى و قيمة متوسط ذروة حركة حلقة الصمام ثلاثى الشرف الانقباضية بمقدار  $15 \leq$  مم و قيمة البعد الداخلى للبطين الأيمن  $>35$  مم و مقياس ضغط الدم بالشريان الرئوى  $>50$  مم زئبق، عدم وجود اختلال من الدرجة الثالثة بوظيفة البطين الأيسر الانبساطية و وجود تأخير بين الحاجز بين البطينين و الجدار الخلفى للبطين الأيسر بمقدار  $130 \leq$  ميلي ثانية و وجود تأخير بين البطينين بمقدار  $40 \leq$  ميلي ثانية و وجود تأخير فى انقباض الجدار الطرفى للبطين الأيسر عن الحاجز بين البطينين بمقدار  $60 \leq$  ميلي ثانية و الإصابة بمرض اعتلال عضلة القلب التوسعى وأخيرا وجود وصلة البطين الأيسر للجهاز فى مكانها الأمثل.

بينما في التحليل الانحدارى متعدد المتغيرات الإسمية كانت المؤشرات المستقلة للتنبؤ المسبق بالإستجابة لزرع جهاز إعادة مزامنة القلب هي كلا مما يلي:

زيادة مدة اشارة البطين QRS فى تخطيط القلب الكهربى بمقدار 150 ميلي ثانية أو أكثر وعدم وجود مرض الانسداد الرئوى المزمن و عدم وجود تاريخ مرضى وأمراض الكلى و انتظام ضربات القلب وفقا للنظام الجيب أذينى و قيمة متوسط ذروة حركة حلقة الصمام ثلاثي الشرف الانقباضية بمقدار  $15 \leq$  مم

و لقد استطعنا انشاء مؤشر متعدد النقاط للتنبؤ باستجابة المرضى لزرع جهاز إعادة مزامنة القلب و يتكون المؤشر من مجموع نقاط معينة لمجموعة المؤشرات المستقلة التى تنتبأ بالاستجابة للجهاز مضاف إليها الجنس الانثوى و انسداد الفرع الضفيرى الأيسر بتخطيط القلب الكهربى على ان تمنح نقطة واحدة لكل مؤشر متوفر لدى المريض قبل زرع الجهاز باستثناء زيادة مدة اشارة البطين QRS فى تخطيط القلب الكهربى بمقدار 150 ميلي ثانية أو أكثر يمنح درجتان حال وجوده و بذلك يكون الحد الأقصى هو 9 نقاط. و قد استجاب للجهاز 97.5% من المرضى الذين حصلوا على 6 نقاط أو أكثر فى حين استجاب للجهاز 40.7% فقط من المرضى الذين حصلوا على اقل من 6 نقاط.

الاستنتاجات:

العلاج عن طريق زرع جهاز إعادة مزامنة القلب هو إجراء فعال لعلاج حالات فشل القلب الانقباضى. يوجد مجموعة جيدة من المؤشرات التى يمكن استخدامها للتنبؤ باستجابة المرضى لزرع جهاز إعادة مزامنة القلب قبل القيام بزراعته. تجميع المؤشرات فى نظام جديد متعدد النقاط قد يكون طريقة سهلة لإختيار المرضى قبل زرع جهاز إعادة مزامنة القلب لزيادة نسبة الاستجابة له.

## لجنة الحكم

الأستاذ الدكتور/ مصطفى محمد نوار

أستاذ أمراض القلب و الأوعية الدموية

كلية الطب

جامعة الإسكندرية

الأستاذ الدكتور/ طارق حسين الزواوى

أستاذ أمراض القلب و الأوعية الدموية

كلية الطب

جامعة الإسكندرية

الأستاذ الدكتور/ أحمد عبد العزيز

أستاذ الحالات الحرجة

كلية الطب

جامعة عين شمس

## المشرفون

الأستاذ الدكتور/ مصطفى محمد نوار

أستاذ أمراض القلب و الأوعية الدموية

كلية الطب

جامعة الإسكندرية

الأستاذ الدكتور/صلاح محمد الطحان

أستاذ أمراض القلب و الأوعية الدموية

كلية الطب

جامعة الإسكندرية

الأستاذ الدكتور/ محمد ابراهيم لطفى

أستاذ أمراض القلب و الأوعية الدموية

كلية الطب

جامعة الإسكندرية

# مؤشرات الإستجابة لزرع جهاز تنسيق القلب فى مرضى فشل القلب

## رسالة

مقدمة لكلية الطب-جامعة الإسكندرية  
إيفاءا جزئيا لشروط الحصول على درجة

دكتوراه فى أمراض القلب

مقدمة من

على احمد على حسن ابو الهدى  
ماجستير أمراض القلب و الأوعية الدموية  
مدرس مساعد أمراض القلب  
كلية الطب جامعة الإسكندرية

كلية الطب  
جامعة الإسكندرية

2015